Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and the performance of its RexMD brand was misleading, as it did not disclose significant operational challenges [2]. Operational Challenges - The lawsuit highlights that LifeMD faced increasing customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. Stock Price Impact - The alleged misleading information came to light on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The company's management attributed this to "temporary elevated customer acquisition costs" and refund issues, resulting in a stock price drop of over 44% the following day [4]. Investor Recovery - For investors who incurred significant losses during the specified period, the lawsuit presents an opportunity for potential recovery of damages [5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims against LifeMD, focusing on whether the company was aware of but failed to disclose key operational issues [6].

LFMD investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition cost ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook, which highlighted a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand, was misleading as it did not disclose significant operational challenges [2]. Operational Challenges - The lawsuit contends that LifeMD faced increasing customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. Stock Price Impact - The alleged misleading information came to light on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and refund issues, resulting in a stock price drop of over 44% the following day [4]. Investor Recovery - For investors who incurred significant losses during the specified period, the lawsuit presents an opportunity for potential recovery of damages [5].

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=172059&from=3 CLASS PERIOD: May 7, 2025 to August ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit claims that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook, leading to a significant drop in share price [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs [3]. - Following the revelation of the true facts, LifeMD's shares plummeted by 44%, equating to a loss of $5.31 per share in a single trading session [3].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., focuses on the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's alleged deception became apparent on August 5, 2025, when it reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and issues with patient refunds [4]. - Following the earnings announcement, LifeMD's stock price dropped by over 44% the next day, reflecting investor reaction to the disclosed operational issues [4]. Investor Recovery Opportunity - The lawsuit provides an opportunity for investors who suffered substantial losses during the specified period to seek recovery of damages [5]. - Hagens Berman, the firm investigating these claims, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth, leading to a significant decline in stock price in August 2025 [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, and seeks to recover damages for investors who incurred substantial losses during this timeframe [2][8]. Financial Performance and Allegations - On May 6, 2025, LifeMD reported strong first-quarter results and raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [5]. - The lawsuit argues that this optimistic outlook was misleading due to undisclosed ongoing business challenges, including rising customer acquisition costs and high patient refund rates [6][9]. Stock Price Impact - Following the announcement of disappointing second-quarter results on August 5, 2025, which included missed revenue and earnings estimates and a reduction in full-year guidance, LifeMD's stock price fell by over 44% the next day [7][6]. Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims on behalf of affected investors, focusing on whether LifeMD's management accurately represented its financial guidance amid rising costs and refund issues [10][11]. - Whistleblowers with non-public information regarding LifeMD are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who purchased LifeMD securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, particularly concerning customer acquisition costs [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]

, /PRNewswire/ -- Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Why:Â Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the im ...